Assertion Contradicted AI assessment confidence: 95% certainty 4/5 debate potential 1/5

Nate Chang: Biotech M&A deals totaled $123 billion in 2018

Nate Chang · What’s with All the Bio M&A in 2019?: A Quick Take · Feb 28, 2019 · at 9:23

Nate Chang, an expert on the Andreessen Horowitz bio team, provides baseline figures for total biotech M&A transaction volume in 2018.

0:00 / 0:07exact quote · 7.8s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“So in 2018, the industry announced one hundred twenty three billion of MNA transactions.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

The biotech industry announced $123 billion in total M&A transactions in 2018.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim states that the biotech industry announced $123 billion in total M&A transactions in 2018. Industry data reveals that $123 billion was the total reported M&A deal value for the first quarter (Q1) of 2018 alone, according to Clarivate / Cortellis Deals Intelligence. For the full year of 2018, industry reports (including EY, EvaluatePharma, Biotechgate, and Informa) reported total M&A transaction values ranging between $136.35 billion and $265 billion. Therefore, $123 billion significantly underestimates the total 2018 full-year M&A volume.

Clarivate / Cortellis Deals Intelligence reported $123 billion in M&A deals for Q1 2018 alone.
Full-year 2018 life sciences and biotech M&A transaction totals reported by major industry trackers (EY, EvaluatePharma, Biotechgate, Informa) ranged from $136.35 billion to $265 billion.

Checked against

[1] a16z.com [2] clarivate.com [3] fenwick.com [4] sustainalytics.com [5] qad.com [6] biotechgate.com

"EY" 2018 total biotech M&A value OR billion a16z podcast Nate Chang 123 billion 2018 biotech M&A "2018" biotech "M&A" total "billion" report EY Firepower 2019 report "123 billion" OR "2018" biotech M&A

assessed as of 2026-07-28

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

biotech industry MNA transactions

⚑ Spot an error? Report it

More from Nate Chang

Assertion Partly supported

Chang: Pharma Acquirers Strengthened Position During Q4 2018 Market Downturn

“I think the buyer psyche changed too, specifically in the fourth quarter where across all sectors of the market saw a downturn in, in trading, but I think the buyer universe actually strengthened across pharma.”

Nate Chang Feb 28, 2019 ▶ 2:39 What’s with All the Bio M&A in 2019?: A Quick Take

Insight

Chang: Pharma Buyers Acquire Biotech Startups to Control Drug Launch Messaging

“So I think part of it also is buyers want to control the launch and control the commercial message.”

Nate Chang Feb 28, 2019 ▶ 3:37 What’s with All the Bio M&A in 2019?: A Quick Take

Insight

Chang: Gene therapy modalities create moats providing sustained cash flows

“If you actually think about gene therapy and new technologies, they are creating the moat. Meaning, for example, Avexis and SMA, they are the, probably the leading gene therapy program out there, and they want to continue building that franchise and have not o…”

Nate Chang Feb 28, 2019 ▶ 4:17 What’s with All the Bio M&A in 2019?: A Quick Take

Opinion

Chang: Spark Therapeutics' Philadelphia manufacturing plant was a key acquisition asset

“If you actually look at Spark, it's, it definitely has its anchor in gene therapy, but I think the thing that gets underappreciated in biopharma is downstream capabilities, and so they have a manufacturing facility on Market Street in Philadelphia, and I think…”

Nate Chang Feb 28, 2019 ▶ 7:41 What’s with All the Bio M&A in 2019?: A Quick Take

Insight

Chang: Bio platforms require end-to-end operational solutions, not just discovery

“The platform is not just an enabling technology to source and discover new drugs, but it's also the breadth of end to end solutions for modality.”

Nate Chang Feb 28, 2019 ▶ 8:10 What’s with All the Bio M&A in 2019?: A Quick Take

Assertion Supported

Chang: Novartis acquired AAA and Endocyte to secure radioisotope supply chains

“He made two acquisitions in the radio label target oncology space. So with AAA and Endocyte being the most recent acquisition they were able to secure that supply chain for that specific radio isotope.”

Nate Chang Feb 28, 2019 ▶ 8:49 What’s with All the Bio M&A in 2019?: A Quick Take

Nate Chang: Biotech M&A deals totaled $123 billion in 2018

More from Nate Chang

Turn any episode into a week of clips.